Invesco Fund's $102.1 Million FormFactor Exit Tops Buys
Invesco's small-cap momentum fund exited FormFactor while adding to Viasat and other stocks, highlighting a sharp difference in reported trade sizes.

The Invesco S&P SmallCap Momentum ETF sold out of FormFactor for $102.1 million while buying $4.4 million of Viasat and $2.9 million each of Victoria's Secret and Protagonist Therapeutics.
The Invesco S&P SmallCap Momentum ETF (XSMO; exchange not supplied) made a much larger move out of FormFactor than into the companies highlighted in its latest reported purchases. The fund sold out of FormFactor (FORM; exchange not supplied) for $102.1 million, alongside smaller purchases of Viasat, Victoria's Secret and Protagonist Therapeutics.
The contrast matters more than the purchase headline alone suggests. Buying additional shares changes an existing allocation; selling out removes a holding altogether. For investors assessing the fund's changing exposure, the complete exit is therefore a distinct portfolio decision, not simply the other side of a similarly sized purchase.
The fund bought $4.4 million of Viasat (VSAT; exchange not supplied) on Oct. 6 and $2.9 million each of Victoria's Secret (VSXY; exchange not supplied) and Protagonist Therapeutics (PTGX; exchange not supplied), according to GuruFocus. The available figures establish the transactions, but not the reasons behind them or the fund's complete trading activity.
The full exit is the larger portfolio change
For scale, an illustrative sum of the disclosed purchases comes to $10.2 million. That combines the Viasat purchase with the equal-sized additions to Victoria's Secret and Protagonist Therapeutics. The FormFactor sale was substantially larger than those purchases combined.
That comparison is useful, but it is not a cash-flow statement for the fund. The disclosed trades do not establish that the FormFactor proceeds financed these particular purchases. Nor do they establish how much cash the fund retained, whether it bought other securities, or whether investor subscriptions and withdrawals affected the transactions.
The distinction also prevents a misleading conclusion about investor demand. An ETF selling a portfolio holding is not, by itself, evidence that investors are pulling money out of the ETF. Portfolio transactions and flows into or out of a fund are separate measures, even though both can influence the securities it holds.
The clearest supported conclusion is narrower: FormFactor ceased to be a holding following the reported sale, while the fund committed additional money to the named purchase targets. Without a complete holdings comparison, there is no basis for describing the fund's overall exposure as more concentrated or more diversified.
Viasat fell at the next available close
The most recent market snapshot is the Oct. 7, 2026 close, with last trades timestamped at 20:00 GMT. At that close, Viasat was down 4.72% for the session. Its decline followed the dated Oct. 6 purchase, but the supplied data do not show the fund's execution price or the value of its Viasat position before and after the trade.
Consequently, the daily share move cannot be treated as the return on the newly purchased shares. A closing-price change measures movement from the previous close, whereas an investor's gain or loss depends on the actual purchase price. The transaction amount alone does not bridge that gap.
The other purchase targets moved in the opposite direction in the same market snapshot. Victoria's Secret closed up 0.82%, and Protagonist Therapeutics closed up 1.61%. Those gains show that the named additions did not behave uniformly during the latest session; they do not establish that the purchases themselves produced those returns.
The other purchase targets moved in the opposite direction in the same market snapshot.
FormFactor closed down 1.06%. Its decline likewise does not prove that the exit was well timed. The available facts do not provide the sale's execution price, the fund's original cost, or the return earned while it held the position. Judging the trade would require that information rather than a subsequent daily percentage alone.
The fund lagged the supplied benchmark proxies
XSMO closed down 1.36% in the Oct. 7 snapshot. The supplied benchmark proxies also declined: the S&P 500 proxy lost 0.24%, the Nasdaq 100 proxy fell 0.25%, and the Dow 30 proxy dropped 0.69%. The fund's decline was steeper than each of those broad-market readings.
That provides context for the session, not an explanation of the fund's performance. A fund return reflects its wider portfolio, and the reported transactions cover only selected names. Assigning the decline to Viasat, or crediting the rising purchase targets with offsetting it, would require position weights and a fuller performance breakdown.
The small-cap momentum mandate also calls for care when making comparisons. Momentum investing generally emphasizes securities with stronger recent price performance. Broad-market proxies can help describe the trading backdrop, but they do not establish whether a specialized fund met its own investment objective.
Equally, the fund's name does not reveal why any particular holding was added or removed. A portfolio change could reflect the implementation of investment rules or other portfolio needs. The supplied facts do not identify a rebalance, a change in selection criteria, or a discretionary judgment about any company's prospects.
Updated holdings will show the lasting effect
The next useful evidence is an updated holdings record. For Viasat, that would show whether the additional purchase materially changed its share of the portfolio. The same comparison would help assess the importance of the Victoria's Secret and Protagonist Therapeutics purchases relative to the fund's existing allocations.
For FormFactor, the reported full exit already answers whether the position remained after the sale. What it does not answer is how the fund redistributed the exposure that disappeared. A complete holdings list would reveal where the portfolio ended up, rather than merely where selected transactions occurred.
Investors should also distinguish a momentum fund's trading decisions from a fundamental recommendation on an individual stock. Purchasing a security does not establish a forecast for earnings or business performance, and exiting one does not demonstrate a negative company outlook. No such explanation accompanies the supplied transaction facts.
The strongest takeaway is therefore the asymmetry in the disclosed activity. The Viasat addition is notable, but the much larger FormFactor exit is the more substantial reported change in dollar terms. The latest closing moves add market context; the fund's subsequent holdings will provide the evidence needed to assess the enduring portfolio effect.
Key facts
- Fund's latest close: XSMO: 81.90, currency unspecified; down 1.36% at the Oct. 7, 2026, 20:00 GMT last trade. Exchange not supplied.
- Complete exit: The fund sold out of FormFactor for $102.1 million.
- Viasat purchase: The fund bought $4.4 million of Viasat on Oct. 6.
- Other purchases: The fund bought $2.9 million each of Victoria's Secret and Protagonist Therapeutics.
Frequently asked questions
What transactions did the Invesco S&P SmallCap Momentum ETF report?
The Invesco S&P SmallCap Momentum ETF bought $4.4 million of Viasat on Oct. 6 and $2.9 million each of Victoria's Secret and Protagonist Therapeutics. It also sold out of FormFactor for $102.1 million. The supplied information does not establish the fund's complete trading activity or explain the decisions.
Why is the FormFactor sale important?
The $102.1 million FormFactor sale removed the holding entirely and was substantially larger than the disclosed purchases combined. That makes it a significant reported change in dollar terms. However, without the fund's total assets and previous position weights, the sale cannot be expressed as a share of the overall portfolio.
How did Viasat perform after the dated purchase?
Viasat closed down 4.72% in the Oct. 7, 2026 market snapshot, following the fund's Oct. 6 purchase. That daily decline is not the fund's return on its newly acquired shares. The supplied information does not include the execution price, share count, or the fund's earlier cost basis.
How did the other named stocks perform at the latest close?
At the Oct. 7, 2026 close, Victoria's Secret gained 0.82%, Protagonist Therapeutics gained 1.61%, and FormFactor fell 1.06%. Those figures describe each stock's daily movement, not the returns achieved on the fund's transactions. Purchase and sale execution prices were not included in the supplied information.
Does the FormFactor exit mean investors withdrew money from XSMO?
No such conclusion follows from the reported sale. A fund's purchase or sale of a portfolio security is different from investors adding or withdrawing money from the fund itself. The supplied facts establish a complete FormFactor exit but provide no subscription, redemption, or overall fund-flow figures.
What information would help explain the portfolio changes?
Updated holdings, previous position weights, execution prices, and a complete transaction record would help establish the lasting effect of the reported trades. An explanation of the fund's selection or rebalancing decisions would also be useful. The available facts do not identify why FormFactor was removed or why the other positions were increased.
Sources
Photo: AlphaTradeZone · Pexels Licence — source


